{"Title":"Dova Pharmaceuticals","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"7","Founded":"","Address":"","Phone":"(919) 806-4487","Web_address":"http://www.dova.com","Market_cup":"$424.8mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-27.5 mil (last 12 months)","Symbol":"DOVA","Exchange":"NASDAQ","Shares":"4.4","Price_range":"$17.00 - $17.00","Est_volume":"$75.1 mil","Manager":"J.P. Morgan/ Jefferies/ Leerink Partners","CO_managers":"-","Exp_to_trade":"6/29/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Our drug candidate, avatrombopag, which we acquired from Eisai, Inc., or Eisai, in March 2016, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that we are developing for the treatment of thrombocytopenia."}